The concept of using thyroid-stimulating hormone (TSH) receptor antagonists in the management of Graves' disease is intriguing. Therefore, we investigated a TSH receptor antagonist derived from human chorionic gonadotropin (hCG) with respect to TSH receptor binding, adenylate cyclase activity, thyroid hormone release, and HLA class II antigen expression in vitro and in an in vivo model.
1. Abbreviations used in this paper: bTSH, bovine thyroid-stimulating hormone; hCG, human chorionic gonadotropin; HF, hydrogenfluoride; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.
in an enhancement of the synthesis and secretion of thyroid hormones. Basically, the same mechanisms are operative also under pathological conditions in patients with Graves' disease, because thyroid-stimulating immunoglobulins bind to the TSH receptor, mimic the actions ofTSH and induce an uncontrolled hyperstimulation ofthe thyroid gland (1) . In addition to their role in maintaining thyroid hyperfunction, Graves' immunoglobulins are also believed to propagate the underlying immunological disorder by enhancing thyroid antigen presentation, particularly aberrant expression of HLA class II antigens on the surface of thyrocytes (2) . In this respect, TSH is also capable of increasing y-interferon induced HLA-DR expression by thyrocytes suggesting that this effect may be mediated via TSH receptor (3) . Hence, TSH receptor antagonists would theoretically offer an ideal approach to treating Graves' disease. In fact, over the past decades several compounds have been described that are capable of inhibiting the binding of labeled TSH to its receptor and of blocking TSH-stimulated adenylate cyclase activity, among them mainly deglycosylated forms of TSH, synthetic peptides representing parts of the alpha-or beta-subunit of TSH, and variants ofhuman chorionic gonadotropin (hCG) (4) (5) (6) (7) (8) (9) . For some ofthese agents an efficacy ofblocking the response to Graves' immunoglobulins has been investigated, too (10, 1 1).
However, in this respect an in vivo bioactivity of these agents has never been shown and is unlikely to exist considering their limited persistence in the circulation. In the present studies, we have therefore attempted to obtain by chemical modification of the hCG molecule a TSH receptor antagonist that would combine the properties of a strong thyroid inhibitory activity and a sufficient plasma survival rate to retain some bioactivity in vivo. For this purpose, we investigated the effects of carbohydrate modified hCG variants on human thyroid in vitro with respect to TSH receptor binding, formation of the second messenger cAMP, and hormonal endpoint response, i.e., T3 release. In addition, we studied their ability to inhibit the binding of '25I-asialo-hCG to liver membranes, a likely marker for their in vivo turnover rate. By these means we succeeded in identifying variant forms of hCG, asialoagalactohCG, and deglycosylated hCG, that seemed to offer some potential to block thyroid stimulation in vivo. AsialoagalactohCG was then tested in the nude mouse model to determine its biological activity under in vivo conditions. Thereby, we assessed its capability to inhibit both stimulation of thyroid hormone production by bTSH and expression of HLA-DR antigen on human thyrocytes induced by bTSH and -y-interferon.
Methods its purified ,3-subunit from the Center of Population Research, National Institute ofChild Health and Human Development. Highly purified bTSH for radioiodination (-30 Preparation ofhCG and its variantforms. Purified hCG (hCG) was isolated from crude hCG by sequential chromatography on columns of DEAE-52 and Sephadex G-100 and was indistinguishable from hCG CR 123 (NIH) in its immunological and biological properties, as has been described in detail previously (9) . To obtain asialo-hCG, hCG was desialylated according to the method of van Hall et al. (12) following a protocol we had previously employed (9, 13): 10 mg of hCG were incubated in 0.1 M Na-acetate buffer, pH 5.6, at 37°C for 30 min, together with 0.2 IU of immobilized neuraminidase from Clostridium perfringens. The sialic acid content was determined before and after neuraminidase digestion by the colorimetric method of Warren after acid hydrolysis (0.1 N H2SO4, 80°C, 1 h) (14) . The removal of> 80% of the original sialic acid was documented.
Asialoagalacto-hCG was then prepared by further enzymatic digestion of asialo-hCG with ,B-galactosidase from Aspergillus niger. Initially, asialo-hCG (5 mg) was treated with the enzyme (1 IU/ml, prewashed with incubation buffer) in 0.05 M Na-acetate buffer, pH 4.6, at 37°C for 1-48 h, following the method of Bahl (15) (procedure 1). Later, this procedure was modified to digestion at room temperature (procedure 2). The reaction was stopped by removing the enzyme with the use of an ultrafiltration chamber (Amicon Corp., Danvers, MA) (membrane YM 100, cut-off 100,000 mol wt). The material was then concentrated by ultrafiltration with a PM 10 membrane (cut-off 10,000 mol wt) and Iyophilized. Galactose concentrations released during /3-galactosidase digestion were measured by the copper reduction method of Somogyi and Nelson (15, 16) . During an incubation of 24 h -80% ofthe original galactose residues were removed. For all biological studies material that has been digested at 20°C for 24 h was used. Deglycosylated hCG was prepared according to the hydrogen fluoride-method of Keutmann and co-workers (17) , as described in detail in a recent paper of ours (18) . This method removes -60-80% of total carbohydrate with substantial amounts ofN-acetylglucosamin and N-acetylgalactosamine still remaining attached.
Isoelectricfocusing (IEF) and immunoblotting. IEF was performed on polyacrylamide gels as described in detail elsewhere (19) Immunoradiometric assays for hCG and its free beta-subunit. The immunological activities of hCG preparations were assessed by immunoradiometric assays (IRMAs), specific for holo-hCG and free betasubunit of hCG, respectively. Monoclonal antibodies employed, i.e., 11/6 (against holo-hCG and LH), 3/6 (hCG and /3-subunit), 12/17 (hCG and /-subunit), and 2/6 (specific for the /3-subunit of hCG), were raised and purified by Dr. K. Siddle, University of Cambridge, UK, as reported previously (21) . Assay procedures and assay characteristics have been described in detail in previous reports from our laboratory (22, 23) . The assay, which employs the monoclonal antibodies, 3/6 as solid phase antibody and 1 1/6 as tracer, measures holo-hCG with negligible cross-reactivity with free beta-subunit of hCG (< 0.01%). The second assay, using 2/6 as solid phase antibody and 12/17 as tracer, is specific for the free beta-subunit of hCG its cross-reactivity with holohCG being only 0.4% (23) . Radioiodination (9) .
Binding studies to human thyroid membranes. Human thyroid tissue obtained at surgery from patients with endemic goiter was processed to a 10,000 g particulate fraction, as described in detail previously (9, 13). Binding of '25I-bTSH (3 X 10-" M) to the thyroid membrane fraction Mg protein per 0.3 ml) was studied in 50 mM Tris-acetate-0.1% BSA buffer, pH 7.45, for 18 h at 22°C, conditions which have been reported to expose the high affinity sites of the TSH receptor (9, 25) . Nonspecific binding was measured in the presence of excess unlabeled bTSH (1.66 IU/ml).
Binding studies to rat liver membranes. To study the influence of various inhibitors on the binding of '25I-asialo-hCG (3 X 101 M) a membrane fraction was prepared from rat liver, as described in detail previously (13 Atkinson and Kendall-Taylor (27), as described in detail previously (19) . Thyroid slices (1 X 1 x 0.5 mm) were incubated with the various inhibitors in a two chamber dialysis system in modified Earles' buffer containing in addition 2 g/liter gelatine, 2 g/liter glucose, 100 IU/liter insulin and antibiotics (penicilline and streptomycine) under 95% OJ 5% CO2 atmosphere, for 5 h at 370C. Quadruplicate determinations were performed for each point. T3 released into the medium was measured by a sensitive RIA after equilibrium dialysis for free hormones.
In vivo studies ofthyroid hormone production and HLA-DR expression in the nude mouse. Normal human thyroid tissue obtained at surgery (neck dissection) from patients with head and neck cancer was transplanted to athymic nude mice (strain NMRI, age 5-6 wk, weight 28-30 g), with each animal receiving two transplants of a size of -4 x 3 x 2 mm. 8 wk after transplantation, mice were injected intravenously on two consecutive days with saline (0.1 ml), bTSH (0.1 mIU/ animal) or various doses of asialoagalacto-hCG (0.25, 0.5, 1 mg/animal) alone or followed by 0.1 mIU of bTSH 5 min later. In another series of animals, bTSH dose was increased to 100 mIU per animal to find out if a higher TSH dose may overcome the thyroid blockade by asialoagalacto-hCG indicating a competitive mode of action of the inhibitor. On the second day of the experiment, 5 MCi of '3'iodide were given i.v. to label thyroid hormones that were newly synthesized. Thyroxine production was then estimated by measuring "3'I-thyroxine in the serum ofthe animals 24 h after '3'I administration with the use ofa double antibody technique (goat anti-T4-antibody and rabbit anti-goat IgG). Results were related to 1311 content in the serum sample and expressed as a percentage of'311-thyroxine to total radioactivity. At the end ofthe experiment, thyroid transplants were removed, stored frozen (-70'C), and used for histological and histomorphological examinations. Particularly, nuclear volume of thyrocytes was assessed, because this is known to be a sensitive marker of functional stimulation of endocrine glands. This experimental nude mouse model briefly described above has been well standardized and widely employed by our group for studies related to a variety of aspects of the physiology of human thyroid under in vivo conditions, including stimulation of cellular hypertrophy and hormone production by bTSH and other thyroid stimulators (28, 29) .
To study HLA-DR expression by normal human thyroid transplants we followed a recently employed protocol (30 
Results
Evaluation ofoptimum conditionsforpreparation ofasialoagalacto-hCG and characterization ofhCG variants. When asialohCG was treated with ,B-galactosidase according to procedure 1, the majority of the material dissociated into its free subunits as evidenced by a reduced immunological activity in the holohCG specific IRMA (data not shown) and a corresponding increased reactivity in the IRMA specific for the free betasubunit of hCG (Fig. 1 A) . In contrast, galactose digestion at room temperature (procedure 2) over the same period of time released only a proportion of < 4% of free beta subunit (Fig. 1  B) . Therefore, asialoagalacto-hCG obtained by 24 h digestion at 20°C was used for further studies.
hCG, asialo-hCG, asialoagalacto-hCG, and deglycosylated 50 -40 .o. Whereas hCG itself failed to inhibit bTSH stimulation of adenylate cyclase activity in human thyroid membranes, asialohCG, asialoagalacto-hCG, and deglycosylated hCG revealed a concentration-dependent inhibitory effect in this respect. Compared on a weight basis, deglycosylated hCG was the most potent inhibitor ofbTSH action, closely followed by asialoagalacto-hCG, and asialo-hCG was the least potent ofthese inhibitors (Fig. 5) . All substances were unable to stimulate adenylate cyclase activity when tested by themselves in the absence of bTSH (data not shown). Figure 4 . Inhibition of the binding of 125I- Two ofthe inhibitors, asialo-hCG and asialoagalacto-hCG, were also tested for their influence on hormone response to bTSH. They showed a dose-dependent inhibition of bTSH stimulated T3 release in human thyroid slices, as depicted in Fig. 6 .
100-
In vivo studies of thyroid hormone production in the nude mouse. In the nude mouse, bTSH induced a dose-dependent stimulation of thyroxine production as measured by an increase in '311-thyroxine in the serum 24 h after administration of radioactive iodide. This was true for animals with and without human thyroid transplants. However, the magnitude of stimulation was considerably higher in animals bearing transplants. In the absence of transplants basal production of 13'ithyroxine was 10.9±2.4% (mean±SD, n = 3), and stimulation by 0.1 mIU bTSH on two consecutive days, as described under Methods, resulted in an increase to 25±5% (n = 3, P < 0.01). After injections of 0.1 mIU/animal bTSH to animals bearing human thyroid transplants 13'1-thyroxine amounted to 33.3±2.2% (n = 6) of total radioactivity in the serum sample, compared to 13.6±0.96% in the absence of the hormone (n = 3, P < 0.01). Asialoagalacto-hCG when given intravenously before bTSH injections to nude mice bearing transplants was able to reduce the bTSH related rise in serum concentrations of '311-thyroxine in a dose dependent manner, as is shown in Fig.  7 . At the highest dose of asialoagalacto-hCG tested (1 mg/animal) bTSH response was nearly completely abolished (Fig. 7) .
In contrast, basal production of '3'I-thyroxine was not signifi- Thyroxine released into the serum was radioactively labeled, and expressed as percentage of '3'1-thyroxine to total radioactivity in the serum sample, as described under Methods. Results in the bTSH and bTSH plus 1 mg asialoagalacto-hCG group were obtained in six animals (mean±SD), respectively. Values in the other groups represent triplicates.
(0.25 mg, 11.1±2.4%; 0.5 mg, 13.7+0.8%; 1 mg, 13.9±1.0%; basal, 12.9±2.6%; n = 3, P = NS). The hCG block on 131I-thyroxine production was apparently overcome by increasing bTSH dose, and only a minor inhibiting effect of 700 Ag asialoagalacto-hCG was seen in animals treated with 100 mIU bTSH each (bTSH alone, 31.6±1.84%, n = 4, vs. bTSH plus asialoagalacto-hCG, 27 .1+2. 1%, n = 4, P= NS).
In addition, a marked increase in nuclear volumes of thyroid follicular cells was seen in transplants ofanimals receiving bTSH (0.1 mIU), but not in animals that had received combined treatment with asialoagalacto-hCG and bTSH. The data are shown in Table I .
In these experiments, concentrations ofholo-hCG immunoreactivity present in the serum ofthe mice 20 min after asialoagalacto-hCG injections were as follows: 4.6±2.9 ,g/ml (x±SD, n = 3) in animals injected with 0.25 mg, 11.0±4.9 ,g/ml in animals injected with 0.5 mg (n = 3) and 25.5±11.6 jig/ml in animals injected with 1 mg asialoagalacto-hCG (n = 6). As expected, in the groups of animals treated with saline and bTSH alone no hCG-immunoreactivity was found.
Studies ofHLA-DR expression in the nude mouse. To study the effects of asialoagalacto-hCG on HLA-DR expression in human thyroid transplants single injections of bTSH and/or asialoagalacto-hCG were administered, in the absence and presence of y-interferon which was continuously infused, for 3 d. Table II summarizes the results of these experiments. The data show a dose-related inhibition by asialoagalacto-hCG of the bTSH effect on DR expression by thyrocytes in the presence of y-interferon (-75% DR-positive cells). The y-interferon effect alone (-45%), however, was not significantly affected by the hCG variant. Asialoagalacto-hCG alone resulted in a percentage of < 3% DR-positive thyrocytes in the transplants, and so did bTSH alone and saline.
Discussion
In the present studies we describe and characterize a TSH receptor antagonist that was obtained by chemically modifying the hCG molecule and inhibits various responses of human thyroid to bTSH in vitro as well as in a nude mouse model under in vivo conditions. This particular variant ofhCG, asia- loagalacto-hCG, favorably combines the properties of a high affinity for human TSH receptor and a limited affinity for hepatic receptors that are responsible for the extremely rapid plasma clearance of asialo-hCG (32, 33).
The aspects ofthe physiology ofasialoagalacto-hCG related to its interaction with the thyroid TSH receptor have apparently not been examined previously, except for some preliminary results published by our group (34) . Only, some data on the interaction of this hCG variant with the ovarian and testis hCG receptor, mainly ofrat origin, are available (35) (36) (37) (38) . From Table II a methodological point of view it is important to note that previously published procedures for preparing asialoagalactohCG by treating asialo-hCG with f3-galactosidase from Aspergillus niger (15) were somewhat unsatisfactorily employed in our hands as their use resulted in considerable release of free d-subunit which is biologically inactive. This problem, however, could be overcome by introducing a slight modification ofthe protocol performing enzymatic digestion at 220C instead of 370C.
As expected from previously published data (9, 13, 39, 40) , removal of sialic acid from hCG resulted in a sharp enhancement of its affinity for TSH receptor in human thyroid membranes. Removal ofterminal galactose in addition to sialic acid brought only little further increase in affinity for TSH receptor, and so did nearly complete removal ofcarbohydrate by the HF method. With respect to its TSH antagonism, asialoagalactohCG proved at least as potent as asialo-hCG and slightly less potent than deglycosylated hCG asjudged by the abilities ofthe substances to inhibit the stimulation ofadenylate cyclase activity by bTSH in human thyroid membranes. In that respect, asialoagalacto-hCG exhibited a much higher potency than other relatively long-lived TSH receptor antagonists (alpha-BF, asialo-alpha-BF) we had described in a previous report (13) . Another aim of the present study was to document an inhibitory effect of TSH receptor antagonists on bTSH-stimulated hormonal endpoint response, because this was apparently not included in previous studies. Indeed, we could show a dose dependent inhibition of bTSH stimulation of T3 release in human thyroid slices by both asialo-hCG and asialoagalacto-hCG.
Binding studies to rat liver membranes were performed next because a close relation between plasma halflives of hCG forms and their affinities for hepatic receptors for asialoglycoproteins had been well established in a number of previous studies including our own work (13, 32, 33) . Thus, the desialylated form ofhCG, asialo-hCG, binds with high affinity to, and is rapidly cleared by these receptors and as a result has a halflife in the range of minutes only, whereas hCG itself has little affinity for hepatic receptors and survives in the circulation for several hours (41, 42) . As a consequence, asialo-hCG does not retain its in vitro gonadotropic activity in vivo (32, 37, 43) . For asialoagalacto-hCG, however, we found a 300-fold lower affinity for asialo-hCG receptor in rat liver membranes when directly compared with asialo-hCG in the same assay. In that respect, deglycosylation did not lead to any further diminution of hepatic binding. These data underline the essential role of terminal galactose in the interaction of asialoglycoproteins with liver receptors that has previously been described by Ashwell and others (44) .
By taking advantage ofdifferences in carbohydrate requirements for interaction with thyroid TSH receptor and hepatic asialoglycoprotein receptors we succeeded in obtaining two variants ofhCG, asialoagalacto-hCG, and deglycosylated hCG, that exhibited a limited affinity for liver receptors and at the same time retained a strong thyroid inhibitory potency. Experiments that would permit an exact analysis oftheir elimination kinetics or calculation of their plasma half-lives were not performed in the present studies. However, we did measure holohCG immunoreactivities present in the serum of the mice 20 min after injecting asialoagalacto-hCG. As expected, serum concentrations of holo-hCG immunoreactivity were related to the dose of asialoagalacto-hCG administered being at this time -25 gg/ml per mg ofsubstance injected. This is in accord with earlier reports showing significantly prolonged plasma halflives of asialoagalacto-hCG and galactose oxidized hCG variants compared to asialo-hCG (36, 37) .
For in vivo testing as a thyroid blocker, we deliberately selected asialoagalacto-hCG rather than deglycosylated hCG, which appeared at least as good a candidate, mainly for reasons that asialoagalacto-hCG obtained by enzymatic methods was a better defined substance available in higher yield, higher purity, and higher homogeneity than deglycosylated hCG, which had been prepared by a chemical method. The choice of a suitable animal model appeared to be difficult, because a substantial species-related variation in thyroid response to hCG is well known. Thus, intact hCG from pregnancy sources is a stimulator of significant potency in the rodent thyroid in vitro and in vivo (45) (46) (47) (48) , whereas in the human thyroid it was reported to exhibit little, if any, thyrotropic activity (49) (50) (51) . Moreover, desialylation and deglycosylation of hCG increase its agonistic activity measured by cAMP response in rat thyroid cells (FRTL-5) rather than transforming it into a pure antagonist like in the human thyroid (18) .
For those reasons, we were particularly interested to study human thyroid and decided to use the nude mouse bearing human thyroid transplants. In this model, the in vivo effects of bTSH and other thyroid stimulators have been well characterized. Particularly, a functional activity and responsiveness of the human thyroid transplants to bTSH stimulation has been shown previously by histomorphological criteria, '3'iodine scintigraphy and serum thyroid hormone measurements (28, 29, 52, 53) . Thus, '3'iodide administered to the mice, in addition to its uptake by the mouse thyroid, is avidly taken up by the transplants and incorporated into thyroid hormones that are newly synthesized and released into the circulation (28, 53) .
Reflecting transplant function, 131I-thyroxine accumulation measured in the serum 24 h after injecting radioactively labeled iodine was higher in animals bearing human thyroid transplants as compared to mice without transplant, and this difference was even more pronounced upon stimulation by bTSH. Treatment of transplant bearing animals with asialoagalactohCG before bTSH stimulation resulted in a significant, doserelated decrease of 13'I-thyroxine serum concentrations as compared to those in the group of animals treated with bTSH alone. The magnitude of inhibition indicated that both transplant and mouse thyroid were affected. Thus, the TSH antagonistic activity of the hCG variant apparently prevailed over its weak mouse thyroid stimulatory potency under these conditions. The mode of inhibition appeared to be competitive, as it is in vitro (9), because the block ofbTSH stimulation was abolished by increasing bTSH dose. Because '311-thyroxine production was dependent on both the human thyroid transplanted and the mouse thyroid it was desirable to have in addition a measure of the function of the human thyroid transplants themselves. Therefore, we determined the nuclear volumes of thyroid follicular cells in frozen transplant sections. In this respect, bTSH induced cellular hypertrophy of human thyrocytes in the transplants could be prevented by treatment with asialoagalacto-hCG. The data add strong evidence that asialoagalacto-hCG was indeed able to block human TSH receptor in the nude mouse bearing human thyroid transplants. with asialoagalacto-hCG. As expected, there was no complete inhibition of DR expression, because DR expression in response to y-interferon alone was not affected by asialoagalactohCG. This, however, would not necessarily preclude a theoretically possible use of TSH receptor antagonists to control antigen expression in Graves' disease, because reduced antigen expression should result in reduced numbers of T helper cells being activated, and this, in turn, should reduce y-interferon production as well as TSAb production initiating a beneficial cycle which would then repeat itself.
In conclusion, in the present studies we describe the preparation and characterization ofa variant ofhCG, asialoagalactohCG, that antagonizes various effects of bTSH in human thyroid in vitro, and, more importantly, in an in vivo model, the nude mouse bearing human thyroid transplants. The data provide evidence that such a substance may successfully be used in vitro as well as in vivo to block both thyroid hormone production and HLA-DR expression brought about by TSH receptor activation. Hence, the concept of antagonizing actions of thyroid stimulators at the receptor level may warrant further exploration for a possible use in the management of Graves' disease and the present findings may help to eventually obtain a thyroid blocker for clinical application.
